Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome
Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome. // AACE Endocrinology and Diabetes. – URL: https://www.sciencedirect.com/science/article/pii/S3050915726002730?dgcid=rss_sd_all
Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome. AACE Endocrinology and Diabetes. https://www.sciencedirect.com/science/article/pii/S3050915726002730?dgcid=rss_sd_all
“Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome.” AACE Endocrinology and Diabetes.
@article{article32532,
title = {Period Prevalence of Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome},
journal = {AACE Endocrinology and Diabetes},
url = {https://www.sciencedirect.com/science/article/pii/S3050915726002730?dgcid=rss_sd_all}
}